These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15143880)

  • 1. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine in node-positive pancreatic cancer.
    Kurosaki I; Hatakeyama K
    Hepatogastroenterology; 2004; 51(57):634-7. PubMed ID: 15143880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant systemic chemotherapy with gemcitabine for stage IV pancreatic cancer: a preliminary report of initial experience.
    Kurosaki I; Hatakeyama K
    Chemotherapy; 2005 Oct; 51(6):305-10. PubMed ID: 16224180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of postoperative adjuvant chemotherapy with gemcitabine for pancreatic cancer: feasibility and anti-tumor effect].
    Kurosaki I; Tsuchiya Y; Shimizu T; Hatakeyama K
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1201-4. PubMed ID: 15332543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
    Oettle H; Post S; Neuhaus P; Gellert K; Langrehr J; Ridwelski K; Schramm H; Fahlke J; Zuelke C; Burkart C; Gutberlet K; Kettner E; Schmalenberg H; Weigang-Koehler K; Bechstein WO; Niedergethmann M; Schmidt-Wolf I; Roll L; Doerken B; Riess H
    JAMA; 2007 Jan; 297(3):267-77. PubMed ID: 17227978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.
    Fischer R; Breidert M; Keck T; Makowiec F; Lohrmann C; Harder J
    Saudi J Gastroenterol; 2012; 18(2):118-21. PubMed ID: 22421717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
    Okabayashi T; Nishimori I; Nishioka A; Yamashita K; Sugimoto T; Dabanaka K; Maeda H; Kohsaki T; Ogawa Y; Kobayashi M; Onishi S; Hanazaki K
    Oncol Rep; 2008 Sep; 20(3):651-6. PubMed ID: 18695919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
    Oettle H; Neuhaus P; Hochhaus A; Hartmann JT; Gellert K; Ridwelski K; Niedergethmann M; Zülke C; Fahlke J; Arning MB; Sinn M; Hinke A; Riess H
    JAMA; 2013 Oct; 310(14):1473-81. PubMed ID: 24104372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
    Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
    Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
    World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Ohge H; Sueda T
    J Gastrointest Surg; 2009 Jan; 13(1):85-92. PubMed ID: 18704593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma.
    Ozkok S; Demirci S; Yalman D; Zeytunlu M; Nart D; Yuzer Y; Coker A; Goker E
    Tumori; 2010; 96(4):560-7. PubMed ID: 20968135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
    Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Tokumaru T; Iiyama T; Kosaki T; Kobayashi M; Hanazaki K
    World J Surg; 2014 Nov; 38(11):2986-93. PubMed ID: 25104544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC-631570 in advanced pancreatic cancer.
    Gansauge F; Ramadani M; Schwarz M; Beger HG; Lotspeich E; Poch B
    Hepatogastroenterology; 2007; 54(75):917-20. PubMed ID: 17591092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
    J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
    Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study.
    Skau Rasmussen L; Vittrup B; Ladekarl M; Pfeiffer P; Karen Yilmaz M; Østergaard Poulsen L; Østerlind K; Palnæs Hansen C; Bau Mortensen M; Viborg Mortensen F; Sall M; Detlefsen S; Bøgsted M; Wilki Fristrup C
    Acta Oncol; 2019 Jun; 58(6):864-871. PubMed ID: 30905248
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
    Takano S; Togawa A; Yoshitomi H; Shida T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Tomonaga T; Nomura F; Miyazaki M
    Ann Surg Oncol; 2008 Nov; 15(11):3157-68. PubMed ID: 18712570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
    Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
    Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer.
    Ren J; Wu S; Su T; Ding J; Chen F; Li J; Wang Z; Han L; Wu Z
    Cancer Med; 2024 May; 13(9):e7229. PubMed ID: 38698688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.